Is Cormedix Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 4 Wall Street analysts covering (NASDAQ: CRMD) stock is to Strong Buy CRMD stock.
Out of 4 analysts, 1 (25%) are recommending CRMD as a Strong Buy, 3 (75%) are recommending CRMD as a Buy, 0 (0%) are recommending CRMD as a Hold, 0 (0%) are recommending CRMD as a Sell, and 0 (0%) are recommending CRMD as a Strong Sell.
What is CRMD's revenue growth forecast for 2024-2024?
(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of 1,042.89% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.88%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.51%.
Cormedix's revenue in 2023 is $29,702.
In 2024, CRMD is forecast to generate $811,218,222 in revenue, with the lowest revenue forecast at $811,218,222 and the highest revenue forecast at $811,218,222.
What is CRMD's forecast return on assets (ROA) for 2023-2026?
(NASDAQ: CRMD) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.19%.
What is CRMD's Price Target?
According to 4 Wall Street analysts that have issued a 1 year CRMD price target, the average CRMD price target is $14.25, with the highest CRMD stock price forecast at $19.00 and the lowest CRMD stock price forecast at $10.00.
On average, Wall Street analysts predict that Cormedix's share price could reach $14.25 by Nov 15, 2024. The average Cormedix stock price prediction forecasts a potential upside of 338.46% from the current CRMD share price of $3.25.
What is CRMD's forecast return on equity (ROE) for 2023-2026?
(NASDAQ: CRMD) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.